Sudeep Pharma IPO Subscription Day: 1 Check Online

Check Expert’s Verdicts on Sudeep Pharma IPO. 

Here is the Sudeep Pharma IPO launched on 21st November 2025. Bidding for the issue will close on 25th November 2025. The primary aim of the Sudeep Pharma IPO is to raise ₹895.00 crores from the market. Additionally, the Sudeep Pharma IPO has received strong subscription levels, suggesting the shares will likely list at a premium. Scroll down to check the Sudeep Pharma IPO subscription and details. 

Sudeep Pharma IPO Details 

The price band for the Sudeep Pharma IPO has been set at ₹563 to ₹593 per share. Let’s segregate the share quota fixed for different categories of investors. 

Sudeep Pharma IPO Subscription Status

As of now, the Sudeep Pharma IPO has been subscribed to 0.83 times. Of these, 0.93 times are subscribed by retail investors, 1.58 times by non-institutional investors, and 0.08 times by QII (Qualified Institutional Investors).  

The healthy subscription status indicates that investors expect higher returns at the time of the Sudeep Pharma IPO, scheduled to list on 28th November 2025. Tenneco Clean Air India’s IPO also has a positive outlook, with the fresh issue of 16,00,000 shares to raise around Rs 895.00 crores.

Sudeep Pharma IPO GMP Today

We know that higher subscription levels drive grey-market premiums for IPOs. Let’s explore the Sudeep Pharma IPO GMP for 21st November 2025. 

The grey market premium for this IPO is 11.67% or Rs 14 per share. It indicates that the estimated listing price per share is Rs 134. Numerous factors played a pivotal role in the jump in Sudeep Pharma’ GMP. These include higher subscription rates, favourable market sentiment, and investors’ positive attitude towards IPOs. 

About Sudeep Pharma IPO Ltd.

Sudeep Pharma was established in 1989 and is a manufacturer of pharmaceutical excipients, food-grade minerals, and speciality nutrition ingredients serving over 100 countries. The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium. The company supplies over 200 products to a diverse customer base across the pharmaceutical, food, and nutrition sectors. The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.

• Market leadership with a diversified product portfolio in a high-barrier industry
• Distinguished global customer base with long-standing relationships with key customers
• Well-equipped and regulatory-compliant Manufacturing Facilities
• Intense research and development capabilities

Sudeep Pharma Limited Financials

The company’s financial analysis is essential before applying for Sudeep Pharma Limited’s IPO. Refer to the table to learn about Sudeep Pharma Limited’s financial information. 

Explanation

Sudeep Pharma Limited’s revenue increased by 10% from ₹465.38 crore in March 2024 to ₹511.33 crore in March 2025. Moreover, the company’s PAT increased by 4% from ₹133.15 crores to ₹138.69 crores. Investors can analyse other relevant factors and make a decision accordingly.

Technical Indicators

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Sudeep Pharma IPO.

Sudeep Pharma IPO Listing Expectations

Sudeep Pharma IPO Highlights: IPO allotment is still pending, as the bid closes today. However, given the current GMP or market sentiment, it is reasonable to expect higher listing gains for the share. An 18.72% Jump in the GMP of Sudeep Pharma IPO suggests that the estimated listing price per share will be around Rs 111.

It will provide higher listing gains to investors who applied for this IPO. Also, the financial fundamentals of this business made it the experts’ top long-term recommendation. 

Sudeep Pharma IPO Dates

Note: IPO GMP is volatile, driven by market sentiment. Hence, one should conduct their research before investing in it.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY

Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY

Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY

Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY

Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY

Sudeep PharmaIPO IPO GMP: Day 3 IPO Live Updates